Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review
dc.contributor.author | Hoffman, Stephanie | |
dc.contributor.author | Braunreiter, Chi | |
dc.date.accessioned | 2017-10-23T17:31:14Z | |
dc.date.available | 2018-12-03T15:34:05Z | en |
dc.date.issued | 2017-10 | |
dc.identifier.citation | Hoffman, Stephanie; Braunreiter, Chi (2017). "Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review." Research and Practice in Thrombosis and Haemostasis 1(2): 188-193. | |
dc.identifier.issn | 2475-0379 | |
dc.identifier.issn | 2475-0379 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/138884 | |
dc.description.abstract | EssentialsData is scarce on enoxaparin dosing for obese adolescents with venous thromboembolism (VTE).Overweight and obese adolescents treated with reduced enoxaparin dose (RD) were reviewed.Initial enoxaparin doses calculated using actual body weight may be greater than what is needed.Trials are warranted to evaluate RD enoxaparin for overweight and obese adolescents with VTE.BackgroundThe global obesity epidemic has created new challenges, including venous thromboembolisms (VTE) in obese adolescents. The data on whether to reduce the dose of low‐molecular heparin in obese adults is conflicting, and information on adolescent patients is scarce.ObjectivesOur primary goal was to describe dosing, anti‐Xa levels, and outcomes of overweight and obese adolescents who received reduced doses of enoxaparin at the initiation of therapy. The secondary goal was to compare their outcomes to overweight and obese adolescents who received standard 1 mg/kg dosing to determine if future trials for dose reduction are warranted.Patients/MethodsWe performed a retrospective cohort study of overweight and obese patients between the ages of 12 and 18 years old diagnosed with VTE who were treated with reduced dosing (RD) of enoxaparin, comparing their dosing, anti‐Xa levels, and outcomes to overweight and obese adolescents who received standard dosing (SD).ResultsRD patients (n=19) achieved therapeutic mean initial anti‐Xa levels that were similar to SD patients (n=11). Of the RD patients, 53% did not require dose adjustments during treatment. Two RD patients had thrombus progression. A total of 25 patients ultimately completed therapy with RD.ConclusionsFuture trials are warranted to evaluate the efficacy and safety of reduced dosing of enoxaparin to treat overweight and obese adolescents with VTE. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | obesity | |
dc.subject.other | thromboembolism | |
dc.subject.other | thrombosis | |
dc.subject.other | enoxaparin | |
dc.subject.other | adolescent | |
dc.title | Reduced dosing of enoxaparin for venous thromboembolism in overweight and obese adolescents: a single institution retrospective review | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Hematology and Oncology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/138884/1/rth212032_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/138884/2/rth212032.pdf | |
dc.identifier.doi | 10.1002/rth2.12032 | |
dc.identifier.source | Research and Practice in Thrombosis and Haemostasis | |
dc.identifier.citedreference | Bernstein D, Coupey S, Schonberg SK. Pulmonary embolism in adolescents. Am J Dis Child. 1986; 140: 667 – 71. | |
dc.identifier.citedreference | Thompson‐Moore NR, Wanat MA, Putney DR, Liebl PH, Chandler WL, Muntz JE. Evaluation and pharmacokinetics of treatment dose enoxaparin in hospitalized patients with morbid obesity. Clin Appl Thromb Hemost. 2015; 21: 513 – 20. | |
dc.identifier.citedreference | Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2015; 39: 516 – 21. | |
dc.identifier.citedreference | Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low‐molecular‐weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001; 119: 64S – 94S. | |
dc.identifier.citedreference | Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists Conference I on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low‐molecular‐weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med. 1998; 122: 799 – 807. | |
dc.identifier.citedreference | Harenberg J. Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? Yes. J Thromb Haemost. 2004; 2: 547 – 50. | |
dc.identifier.citedreference | Bounameaux H, de Moerloose P. Is laboratory monitoring of low‐molecular‐weight heparin therapy necessary? No. J Thromb Haemost. 2004; 2: 551 – 4. | |
dc.identifier.citedreference | Spentzouris G, Scriven RJ, Lee TK, Labropoulos N. Pediatric venous thromboembolism in relation to adults. J Vasc Surg. 2012; 55: 1785 – 93. | |
dc.identifier.citedreference | Barras MA, Kirkpatrick CM, Green B. Current dosing of low‐molecular‐weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol. 2010; 69: 520 – 8. | |
dc.identifier.citedreference | Lewis TV, Johnson PN, Nebbia AM, Dunlap M. Increased enoxaparin dosing is required for obese children. Pediatrics. 2011; 127: e787 – 90. | |
dc.identifier.citedreference | Mushtaq A, Vaughns JD, Ziesenitz VC, Nadler EP, van den Anker JN. Use of enoxaparin in obese adolescents during bariatric surgery–a pilot study. Obes Surg. 2015; 25: 1869 – 74. | |
dc.identifier.citedreference | Barlow SE; Expert Committee. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007; 120 ( Suppl 4 ): S164 – 92. | |
dc.identifier.citedreference | Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009; 4: 1832 – 43. | |
dc.identifier.citedreference | Goldenberg NA, Abshire T, Blatchford PJ, et al. Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids‐DOTT trial): pilot/feasibility phase findings. J Thromb Haemost. 2015; 13: 1597 – 605. | |
dc.identifier.citedreference | Richard AA, Kim S, Moffett BS, Bomgaars L, Mahoney D Jr, Yee DL. Comparison of anti‐Xa levels in obese and non‐obese pediatric patients receiving treatment doses of enoxaparin. J Pediatr. 2013; 162: 293 – 6. | |
dc.identifier.citedreference | Nowak‐Göttl U, Bidlingmaier C, Krümpel A, Göttl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol. 2008; 153: 1120 – 7. | |
dc.identifier.citedreference | Mismetti P, Quenet S, Levine M, et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta‐analysis. Chest. 2005; 128: 2203 – 10. | |
dc.identifier.citedreference | Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low‐molecular‐weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta‐analysis. Am J Med. 1996; 100: 269 – 77. | |
dc.identifier.citedreference | Prentice AM. The emerging epidemic of obesity in developing countries. Int J Epidemiol. 2006; 35: 93 – 9. | |
dc.identifier.citedreference | Ogden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988‐1994 through 2013‐2014. JAMA. 2016; 315: 2292 – 9. | |
dc.identifier.citedreference | Yang G, De Staercke C, Hooper WC. The effects of obesity on venous thromboembolism: a review. Open J Prev Med. 2012; 2: 499 – 509. | |
dc.identifier.citedreference | Eichinger S, Hron G, Bialonczyk C, et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med. 2008; 168: 1678 – 83. | |
dc.identifier.citedreference | Borch KH, Braekkan SK, Mathiesen EB, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: the Tromso study. J Thromb Haemost. 2009; 7: 739 – 45. | |
dc.identifier.citedreference | Vu LT, Nobuhara KK, Lee H, Farmer DL. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg. 2008; 43: 1095 – 9. | |
dc.identifier.citedreference | Halvorson EE, Ervin SE, Russell TB, Skelton JA, Davis S, Spangler J. Association of obesity and pediatric venous thromboembolism. Hosp Pediatr. 2016; 6: 22 – 6. | |
dc.identifier.citedreference | Merkel N, Gunther G, Schobess R. Long‐term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol. 2006; 115: 230 – 6. | |
dc.identifier.citedreference | Monagle P, Chan AK, Goldenberg NA, et al. Physicians ACoC. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence‐Based Clinical Practice Guidelines. Chest. 2012; 141: e737S – 801S. | |
dc.identifier.citedreference | Sanderink GJ, Le Liboux A, Jariwala N, et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002; 72: 308 – 18. | |
dc.identifier.citedreference | Bazinet A, Almanric K, Brunet C, et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005; 116: 41 – 50. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.